IMNN Imunon Inc

Price (delayed)

$2.09

Market cap

$8.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.45

Enterprise value

$4.9M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of ...

Highlights
The company's EPS has surged by 69% YoY and by 20% QoQ
The net income has grown by 18% YoY
Imunon's quick ratio has soared by 130% YoY but it has decreased by 39% from the previous quarter
The equity has dropped by 52% since the previous quarter

Key stats

What are the main financial stats of IMNN

IMNN stock price

How has the Imunon stock price performed over time
Intraday
-0.48%
1 week
-9.13%
1 month
-25.36%
1 year
-91.8%
YTD
-45.14%
QTD
-28.91%

Financial performance

How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.81M
Net income
-$14.64M
Gross margin
N/A
Net margin
N/A
IMNN's operating income is up by 19% YoY
The net income has grown by 18% YoY

Price vs fundamentals

How does IMNN's price correlate with its fundamentals

Growth

What is Imunon's growth rate over time

Valuation

What is Imunon stock price valuation
P/E
N/A
P/B
2.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 69% YoY and by 20% QoQ
The equity has dropped by 52% since the previous quarter
IMNN's price to book (P/B) is 23% lower than its 5-year quarterly average of 3.2 and 21% lower than its last 4 quarters average of 3.1

Efficiency

How efficient is Imunon business performance
The ROE has grown by 20% YoY and by 16% from the previous quarter
Imunon's return on assets has increased by 12% YoY and by 2% QoQ

Dividends

What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNN.

Financial health

How did Imunon financials performed over time
The total assets is 72% more than the total liabilities
Imunon's quick ratio has soared by 130% YoY but it has decreased by 39% from the previous quarter
The current ratio has soared by 81% YoY but it has contracted by 31% from the previous quarter
IMNN's debt is 73% less than its equity
IMNN's debt to equity has soared by 93% QoQ but it has shrunk by 88% YoY
The equity has dropped by 52% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.